Payment overview · 2025
General Payments
$201.19
11 reported records · 8 companies
Healthcare provider profile · identity verified
Amanda D Marshburn, NP
Physician Assistants & Advanced Practice Nursing Providers|Nurse Practitioner|Family · RICHLANDS, NC · NPI 1003362765
Verified facts
What the public records show
CMS Open Payments records show Amanda D Marshburn, NP received $201.19 in general payments during 2025 across 11 reported records.
Sumitomo Pharma America, Inc. accounted for 22.0% of that reported general-payment amount.
The Open Payments records used for this analysis explicitly named 9 associated products.
A separate comparison found the same explicitly named product in public Medicare Part D data: Eliquis, Trelegy Ellipta.
Astellas Pharma US Inc reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported Myrbetriq as an associated drug or biological on 16 records involving 16 distinct recipient NPIs. Public Medicare Part D data also shows 74 claims for Myrbetriq by this doctor in 2024.
GlaxoSmithKline, LLC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported TRELEGY ELLIPTA as an associated drug or biological on 131532 records involving 37148 distinct recipient NPIs. Public Medicare Part D data also shows 68 claims for Trelegy Ellipta by this doctor in 2024.
Novo Nordisk Inc reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported Ozempic as an associated drug or biological on 261625 records involving 77793 distinct recipient NPIs. Public Medicare Part D data also shows 46 claims for Ozempic by this doctor in 2024.
Novo Nordisk Inc reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported Rybelsus as an associated drug or biological on 161257 records involving 55409 distinct recipient NPIs. Public Medicare Part D data also shows 20 claims for Rybelsus by this doctor in 2024.
PFIZER INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported ELIQUIS as an associated drug or biological on 87112 records involving 36032 distinct recipient NPIs. Public Medicare Part D data also shows 70 claims for Eliquis by this doctor in 2024.
PFIZER INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported PAXLOVID as an associated drug or biological on 24465 records involving 15715 distinct recipient NPIs. Public Medicare Part D data also shows 12 claims for Paxlovid by this doctor in 2024.
These records do not establish that a payment influenced prescribing or medical care.
Separate record types
Research & Ownership
Research Payments (direct recipient): not present in the loaded data
Associated Research Funding (for example, named PI): not present in the loaded data
Ownership / Investment: not present in the loaded data
These categories are never added into the General Payments headline. Associated research funding must not be described as money the doctor personally received unless the source record supports that conclusion.
Who paid this doctor?
Companies in 2025 General Payments
| Reported company | Canonical company | Amount | Share | Records | Year |
|---|---|---|---|---|---|
| Sumitomo Pharma America, Inc. | Unresolved — no canonical attribution shown | $44.20 | 22.0% | 2 | 2025 |
| GlaxoSmithKline, LLC. | Unresolved — no canonical attribution shown | $34.53 | 17.2% | 2 | 2025 |
| AstraZeneca Pharmaceuticals LP | Unresolved — no canonical attribution shown | $32.41 | 16.1% | 2 | 2025 |
| Medtronic, Inc. |
Medtronic, Inc. exact · evidence 2025-07-22 |
$22.52 | 11.2% | 1 | 2025 |
| Astellas Pharma US Inc | Unresolved — no canonical attribution shown | $20.23 | 10.1% | 1 | 2025 |
| Novo Nordisk Inc | Unresolved — no canonical attribution shown | $17.16 | 8.5% | 1 | 2025 |
| Exact Sciences Corporation | Unresolved — no canonical attribution shown | $15.38 | 7.6% | 1 | 2025 |
| PFIZER INC. | Unresolved — no canonical attribution shown | $14.76 | 7.3% | 1 | 2025 |
What were the payments for?
Payment categories
| Category | Amount | Records |
|---|---|---|
| Food and Beverage | $201.19 | 11 |
A meal, consulting fee, royalty, and travel payment describe different kinds of reported relationships and should not be interpreted as equivalent.
Analysis 1 · Payment-linked products
Products named in Open Payments records
| Reported product | Type | Reported company | Related amount* | Records | Year |
|---|---|---|---|---|---|
| GEMTESA Normalized: gemtesa |
Drug | Sumitomo Pharma America, Inc. | $44.20 | 2 | 2025 |
Source payment records
|
|||||
| TRELEGY ELLIPTA Normalized: trelegy ellipta |
Drug | GlaxoSmithKline, LLC. | $34.53 | 2 | 2025 |
Source payment records
|
|||||
| INCEPTIV Normalized: inceptiv |
Device | Medtronic, Inc. | $22.52 | 1 | 2025 |
Source payment records
|
|||||
| Veozah Normalized: veozah |
Drug | Astellas Pharma US Inc | $20.23 | 1 | 2025 |
Source payment records
|
|||||
| Wegovy Normalized: wegovy |
Drug | Novo Nordisk Inc | $17.16 | 1 | 2025 |
Source payment records
|
|||||
| BREZTRI Normalized: breztri |
Drug | AstraZeneca Pharmaceuticals LP | $17.09 | 1 | 2025 |
Source payment records
|
|||||
| The Cologuard Plus Collection Kit Normalized: the cologuard plus collection kit |
Device | Exact Sciences Corporation | $15.38 | 1 | 2025 |
Source payment records
|
|||||
| ELIQUIS Normalized: eliquis |
Drug | PFIZER INC. | $14.76 | 1 | 2025 |
Source payment records
|
|||||
| NURTEC ODT Normalized: nurtec odt |
Drug | PFIZER INC. | $14.76 | 1 | 2025 |
Source payment records
|
|||||
* Product-associated amounts are non-additive because one payment record may name more than one product.
These products were named on specific Open Payments records. A named product does not show that the payment influenced treatment or prescribing.
Public prescribing for products named in payments
| Open Payments product | Payment year | Part D brand | Part D year | Claims | Match method | Source |
|---|---|---|---|---|---|---|
| ELIQUIS eliquis |
2025 | Eliquis | 2024 | 70 | exact normalized | Medicare Part D |
| TRELEGY ELLIPTA trelegy ellipta |
2025 | Trelegy Ellipta | 2024 | 68 | exact normalized | Medicare Part D |
The presence of the same drug in both datasets does not show that a payment caused or influenced a prescription.
Analysis 2 · Same-company prescribing overlap
Drugs reported in other payments from the same company that also appear in Medicare Part D
This analysis is independent from products named on this doctor’s individual payment records. A row appears only when the exact Open Payments reporting entity paid this doctor, that same reporting entity reported the drug or biological on at least 10 loaded General Payment records involving at least 2 distinct recipient NPIs, and this doctor has the same non-generic brand in public Part D data. This does not mean the company owns or manufactures the drug.
| Paying company | Payment year | Drug reported by same entity | Open Payments evidence | Part D | Claims | Beneficiaries |
|---|---|---|---|---|---|---|
| Astellas Pharma US Inc Exact reporting entity; no affiliate inference |
2025 | Myrbetriq open payments reported associated product |
CMS Open Payments — General Payments 16 supporting records · 16 recipient NPIs · example record 1238599014 |
Myrbetriq · 2024 Exact normalized brand match · 1 Part D row |
74 | 14 |
| GlaxoSmithKline, LLC. Exact reporting entity; no affiliate inference |
2025 | TRELEGY ELLIPTA open payments reported associated product |
CMS Open Payments — General Payments 131532 supporting records · 37148 recipient NPIs · example record 1190332369 |
Trelegy Ellipta · 2024 Exact normalized brand match · 1 Part D row |
68 | 13 |
| Novo Nordisk Inc Exact reporting entity; no affiliate inference |
2025 | Ozempic open payments reported associated product |
CMS Open Payments — General Payments 261625 supporting records · 77793 recipient NPIs · example record 1188130076 |
Ozempic · 2024 Exact normalized brand match · 1 Part D row |
46 | 12 |
| Novo Nordisk Inc Exact reporting entity; no affiliate inference |
2025 | Rybelsus open payments reported associated product |
CMS Open Payments — General Payments 161257 supporting records · 55409 recipient NPIs · example record 1188130076 |
Rybelsus · 2024 Exact normalized brand match · 1 Part D row |
20 | suppressed by CMS |
| PFIZER INC. Exact reporting entity; no affiliate inference |
2025 | ELIQUIS open payments reported associated product |
CMS Open Payments — General Payments 87112 supporting records · 36032 recipient NPIs · example record 1228794063 |
Eliquis · 2024 Exact normalized brand match · 1 Part D row |
70 | 18 |
| PFIZER INC. Exact reporting entity; no affiliate inference |
2025 | PAXLOVID open payments reported associated product |
CMS Open Payments — General Payments 24465 supporting records · 15715 recipient NPIs · example record 1228794432 |
Paxlovid · 2024 Exact normalized brand match · 1 Part D row |
12 | 12 |
These facts do not show that a payment was for the drug, that the company owns or manufactures the drug, or that a payment caused or influenced prescribing.
Public Medicare Part D data
Provider-and-drug rows loaded for 2024
| Brand | Generic | Claims | Beneficiaries |
|---|---|---|---|
| Atorvastatin Calcium | Atorvastatin Calcium | 293 | 76 |
| Amlodipine Besylate | Amlodipine Besylate | 240 | 70 |
| Levothyroxine Sodium | Levothyroxine Sodium | 235 | 53 |
| Omeprazole | Omeprazole | 188 | 49 |
| Gabapentin | Gabapentin | 180 | 47 |
| Furosemide | Furosemide | 169 | 35 |
| Lisinopril | Lisinopril | 169 | 40 |
| Jardiance | Empagliflozin | 162 | 26 |
| Metoprolol Succinate | Metoprolol Succinate | 146 | 40 |
| Albuterol Sulfate Hfa | Albuterol Sulfate | 145 | 54 |
| Losartan Potassium | Losartan Potassium | 143 | 36 |
| Simvastatin | Simvastatin | 131 | 29 |
| Sertraline Hcl | Sertraline Hcl | 115 | 23 |
| Alprazolam | Alprazolam | 110 | 23 |
| Potassium Chloride | Potassium Chloride | 110 | 35 |
| Prednisone | Prednisone | 108 | 84 |
| Pantoprazole Sodium | Pantoprazole Sodium | 107 | 34 |
| Fluticasone Propionate | Fluticasone Propionate | 106 | 37 |
| Metformin Hcl Er | Metformin Hcl | 106 | 33 |
| Rosuvastatin Calcium | Rosuvastatin Calcium | 100 | 32 |
| Trazodone Hcl | Trazodone Hcl | 100 | 26 |
| Montelukast Sodium | Montelukast Sodium | 88 | 21 |
| Hydrochlorothiazide | Hydrochlorothiazide | 85 | 27 |
| Tamsulosin Hcl | Tamsulosin Hcl | 85 | 23 |
| Esomeprazole Magnesium | Esomeprazole Magnesium | 76 | 17 |
| Metformin Hcl | Metformin Hcl | 76 | 21 |
| Fluoxetine Hcl | Fluoxetine Hcl | 74 | 13 |
| Myrbetriq | Mirabegron | 74 | 14 |
| Pregabalin | Pregabalin | 73 | 16 |
| Pravastatin Sodium | Pravastatin Sodium | 72 | 19 |
| Metoprolol Tartrate | Metoprolol Tartrate | 71 | 17 |
| Eliquis | Apixaban | 70 | 18 |
| Duloxetine Hcl | Duloxetine Hcl | 69 | 15 |
| Trelegy Ellipta | Fluticasone/Umeclidin/Vilanter | 68 | 13 |
| Ondansetron Odt | Ondansetron | 65 | 16 |
| Allopurinol | Allopurinol | 60 | 13 |
| Cyclobenzaprine Hcl | Cyclobenzaprine Hcl | 60 | 26 |
| Mirtazapine | Mirtazapine | 60 | 19 |
| Meloxicam | Meloxicam | 58 | 16 |
| Celecoxib | Celecoxib | 54 | 14 |
| Azithromycin | Azithromycin | 52 | 47 |
| Azelastine Hcl | Azelastine Hcl | 49 | 24 |
| Lisinopril-Hydrochlorothiazide | Lisinopril/Hydrochlorothiazide | 49 | 14 |
| Clonazepam | Clonazepam | 48 | 12 |
| Losartan-Hydrochlorothiazide | Losartan/Hydrochlorothiazide | 48 | 17 |
| Ciprofloxacin Hcl | Ciprofloxacin Hcl | 47 | 36 |
| Citalopram Hbr | Citalopram Hydrobromide | 46 | 14 |
| Escitalopram Oxalate | Escitalopram Oxalate | 46 | 16 |
| Ozempic | Semaglutide | 46 | 12 |
| Amoxicillin-Clavulanate Potass | Amoxicillin/Potassium Clav | 44 | 35 |
| Memantine Hcl | Memantine Hcl | 42 | suppressed |
| Nystatin | Nystatin | 42 | 19 |
| Ventolin Hfa | Albuterol Sulfate | 42 | 16 |
| Mounjaro | Tirzepatide | 38 | suppressed |
| Ropinirole Hcl | Ropinirole Hcl | 36 | suppressed |
| Carvedilol | Carvedilol | 35 | suppressed |
| Diclofenac Sodium | Diclofenac Sodium | 35 | 13 |
| Estradiol | Estradiol | 35 | 14 |
| Glimepiride | Glimepiride | 33 | suppressed |
| Levemir Flexpen | Insulin Detemir | 33 | suppressed |
| Lovastatin | Lovastatin | 33 | suppressed |
| Methocarbamol | Methocarbamol | 32 | suppressed |
| Spironolactone | Spironolactone | 31 | suppressed |
| Ipratropium Bromide | Ipratropium Bromide | 28 | suppressed |
| Naproxen | Naproxen | 28 | suppressed |
| Fluticasone-Salmeterol | Fluticasone Propion/Salmeterol | 27 | suppressed |
| Diltiazem 24hr Er (Cd) | Diltiazem Hcl | 25 | suppressed |
| Synthroid | Levothyroxine Sodium | 25 | suppressed |
| Flecainide Acetate | Flecainide Acetate | 24 | suppressed |
| Xarelto | Rivaroxaban | 24 | suppressed |
| Donepezil Hcl | Donepezil Hcl | 23 | suppressed |
| Finasteride | Finasteride | 23 | suppressed |
| Ibuprofen | Ibuprofen | 23 | suppressed |
| Ezetimibe | Ezetimibe | 22 | suppressed |
| Telmisartan | Telmisartan | 22 | suppressed |
| Breo Ellipta | Fluticasone/Vilanterol | 21 | suppressed |
| Bupropion Xl | Bupropion Hcl | 21 | suppressed |
| Doxycycline Hyclate | Doxycycline Hyclate | 21 | 20 |
| Tizanidine Hcl | Tizanidine Hcl | 21 | suppressed |
| Famotidine | Famotidine | 20 | suppressed |
| Januvia | Sitagliptin Phosphate | 20 | suppressed |
| Nitrofurantoin Mono-Macro | Nitrofurantoin Monohyd/M-Cryst | 20 | 15 |
| Rybelsus | Semaglutide | 20 | suppressed |
| Stiolto Respimat | Tiotropium Br/Olodaterol Hcl | 20 | suppressed |
| Topiramate | Topiramate | 20 | suppressed |
| Benazepril Hcl | Benazepril Hcl | 19 | suppressed |
| Cephalexin | Cephalexin | 19 | 16 |
| Fluconazole | Fluconazole | 19 | 17 |
| Belsomra | Suvorexant | 18 | suppressed |
| Clopidogrel | Clopidogrel Bisulfate | 18 | suppressed |
| Dicyclomine Hcl | Dicyclomine Hcl | 18 | suppressed |
| Epinephrine | Epinephrine | 18 | suppressed |
| Propranolol Hcl | Propranolol Hcl | 18 | suppressed |
| Testosterone Cypionate | Testosterone Cypionate | 18 | suppressed |
| Baclofen | Baclofen | 17 | suppressed |
| Enalapril Maleate | Enalapril Maleate | 17 | suppressed |
| Hydralazine Hcl | Hydralazine Hcl | 17 | suppressed |
| Hydrocodone-Acetaminophen | Hydrocodone/Acetaminophen | 17 | 14 |
| Promethazine Hcl | Promethazine Hcl | 17 | suppressed |
| Rizatriptan | Rizatriptan Benzoate | 17 | suppressed |
| Diazepam | Diazepam | 16 | suppressed |
| Glipizide | Glipizide | 16 | suppressed |
| Tresiba Flextouch U-100 | Insulin Degludec | 16 | suppressed |
| Triamcinolone Acetonide | Triamcinolone Acetonide | 16 | suppressed |
| Vitamin D2 | Ergocalciferol (Vitamin D2) | 16 | suppressed |
| Hydrocortisone | Hydrocortisone | 15 | suppressed |
| Lansoprazole | Lansoprazole | 15 | suppressed |
| Levetiracetam | Levetiracetam | 15 | suppressed |
| Rexulti | Brexpiprazole | 15 | suppressed |
| Valacyclovir | Valacyclovir Hcl | 15 | suppressed |
| Hydroxyzine Hcl | Hydroxyzine Hcl | 14 | suppressed |
| Irbesartan-Hydrochlorothiazide | Irbesartan/Hydrochlorothiazide | 14 | suppressed |
| Lidocaine | Lidocaine | 14 | suppressed |
| Midodrine Hcl | Midodrine Hcl | 14 | suppressed |
| Ranolazine Er | Ranolazine | 14 | suppressed |
| Metronidazole | Metronidazole | 13 | suppressed |
| Tolterodine Tartrate | Tolterodine Tartrate | 13 | suppressed |
| Aimovig Autoinjector | Erenumab-Aooe | 12 | suppressed |
| Etodolac | Etodolac | 12 | suppressed |
| Fluocinolone Acetonide | Fluocinolone Acetonide | 12 | suppressed |
| Hydroxyzine Pamoate | Hydroxyzine Pamoate | 12 | suppressed |
| Levofloxacin | Levofloxacin | 12 | 11 |
| Lorazepam | Lorazepam | 12 | suppressed |
| Omega-3 Acid Ethyl Esters | Omega-3 Acid Ethyl Esters | 12 | suppressed |
| Ondansetron Hcl | Ondansetron Hcl | 12 | suppressed |
| Paxlovid | Nirmatrelvir/Ritonavir | 12 | 12 |
| Premarin | Estrogens, Conjugated | 12 | suppressed |
| Primidone | Primidone | 12 | suppressed |
| Tramadol Hcl | Tramadol Hcl | 12 | suppressed |
| Triamterene-Hydrochlorothiazid | Triamterene/Hydrochlorothiazid | 12 | suppressed |
| Warfarin Sodium | Warfarin Sodium | 12 | suppressed |
| Basaglar Kwikpen U-100 | Insulin Glargine,hum.Rec.Anlog | 11 | suppressed |
| Diltiazem 24hr Er | Diltiazem Hcl | 11 | suppressed |
| Oxybutynin Chloride Er | Oxybutynin Chloride | 11 | suppressed |
| Paroxetine Hcl | Paroxetine Hcl | 11 | suppressed |
| Valsartan-Hydrochlorothiazide | Valsartan/Hydrochlorothiazide | 11 | suppressed |
Timeline
Payment and prescribing data by year
Open Payments and Medicare Part D may refer to different years. They are shown separately rather than aligned as if they describe the same period.
| Year | General Payments | Main payer | Explicit products | Company overlaps | Part D coverage |
|---|---|---|---|---|---|
| 2025 | $201.19 · 11 records | Sumitomo Pharma America, Inc. | BREZTRI, ELIQUIS, GEMTESA, INCEPTIV, NURTEC ODT, TRELEGY ELLIPTA, The Cologuard Plus Collection Kit, Veozah, Wegovy | 6 | — |
| 2024 | — | — | — | — | Complete |
Questions to ask
Questions you could discuss with your doctor
- What role, if any, does Eliquis play in your treatment recommendations for me?
- How do you evaluate evidence when you have a financial relationship with Astellas Pharma US Inc?
- Are there reasonable alternatives I should understand when we discuss treatment options?
- How should I interpret the industry-payment records shown here in the context of my care?
These are general questions generated from reviewed templates. They are not personalized medical advice.
Sources and limitations
How to read this page
- Payment and Medicare prescribing data can cover different years; every comparison shows both years explicitly.
- Part D does not represent a doctor’s entire practice; it excludes many patients and is subject to CMS public-release thresholds.
- Company–drug relationships must have an auditable source, a precise relationship type, and a valid evidence period. Unresolved mappings are not published.
- Generic drug claims are not attributed to a specific manufacturer without manufacturer-level evidence.
- When a source extract is incomplete, missing rows are never treated as proof of no payments or no prescriptions.
Loaded source releases
| Dataset | Year | Publication | Source |
|---|---|---|---|
| CMS Open Payments — General Payments | 2025 | 2026-06-30 | Original source |
| Medicare Part D Prescribers by Provider and Drug | 2024 | 2026-05-06 | Original source |
| NPPES Data Dissemination V2 | current / reference data | 2026-08-10 | Original source |
Full methodology · Questions & answers · Report a possible error